Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Receivables - Other (2017 - 2025)

Historic Receivables - Other for Integra Lifesciences Holdings (IART) over the last 9 years, with Q3 2025 value amounting to $4.9 million.

  • Integra Lifesciences Holdings' Receivables - Other fell 3704.65% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year decrease of 3704.65%. This contributed to the annual value of $6.1 million for FY2024, which is 3343.44% down from last year.
  • According to the latest figures from Q3 2025, Integra Lifesciences Holdings' Receivables - Other is $4.9 million, which was down 3704.65% from $3.5 million recorded in Q2 2025.
  • Integra Lifesciences Holdings' 5-year Receivables - Other high stood at $12.2 million for Q1 2022, and its period low was $3.5 million during Q2 2025.
  • For the 5-year period, Integra Lifesciences Holdings' Receivables - Other averaged around $8.1 million, with its median value being $8.0 million (2021).
  • As far as peak fluctuations go, Integra Lifesciences Holdings' Receivables - Other surged by 8798.28% in 2022, and later crashed by 4728.97% in 2025.
  • Integra Lifesciences Holdings' Receivables - Other (Quarter) stood at $11.4 million in 2021, then fell by 11.3% to $10.1 million in 2022, then fell by 8.78% to $9.2 million in 2023, then tumbled by 33.43% to $6.1 million in 2024, then decreased by 19.82% to $4.9 million in 2025.
  • Its Receivables - Other stands at $4.9 million for Q3 2025, versus $3.5 million for Q2 2025 and $5.1 million for Q1 2025.